HCW Biologics (NASDAQ:HCWB – Get Free Report) will likely be posting its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to post earnings of ($1.35) per share and revenue of $0.12 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.
HCW Biologics (NASDAQ:HCWB – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($11.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.98) by ($9.60). HCW Biologics had a negative net margin of 83.03% and a negative return on equity of 262.33%. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.14 million.
HCW Biologics Stock Down 6.1%
Shares of NASDAQ HCWB opened at $1.08 on Thursday. The stock has a market capitalization of $2.42 million, a price-to-earnings ratio of -0.04 and a beta of 2.31. HCW Biologics has a 52 week low of $1.08 and a 52 week high of $23.94. The firm has a 50-day moving average price of $1.85 and a 200 day moving average price of $4.07.
Analysts Set New Price Targets
A number of research analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a report on Thursday, October 15th. Wall Street Zen raised HCW Biologics from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $30.00.
Get Our Latest Stock Report on HCWB
HCW Biologics Company Profile
HCW Biologics Inc (NASDAQ: HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic inflammation, immune dysfunction and aging. The company’s research is intended to address conditions in which persistent inflammation contributes to disease progression.
HCW Biologics uses its proprietary TOBI platform to design multifunctional fusion proteins that can target inflammatory pathways and modify immune responses. Its development programs have included HCW9218, an investigational immunotherapy designed to combine immune-stimulating activity with inhibition of transforming growth factor beta, a signaling pathway associated with immune suppression and disease progression.
Featured Stories
- Five stocks we like better than HCW Biologics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
